-
公开(公告)号：US20060269540A1
公开(公告)日：2006-11-30
申请号：US10529221
申请日：2003-09-26
Applicant: Bruno Robert , Alena Donda , Valerie Cesson , Jean-Pierre Mach , Maurice Zauderer
Inventor： Bruno Robert , Alena Donda , Valerie Cesson , Jean-Pierre Mach , Maurice Zauderer
CPC classification number: C07K16/30 , C07K14/70539 , C07K2317/54 , C07K2317/55 , C07K2319/00
Abstract: The invention is directed to a compound comprising one or more CD1d complexes in association with an antibody specific for a cell surface marker. The CD1d complexes comprise a CD1d, a β2-microglobulin molecule, and may further comprise an antigen bound to the CD1d binding groove. The invention is further directed to methods of inhibiting or stimulating an immune response with the CD1d-antibody compounds, in particular anti-tumor and autoimmunity responses.
Abstract translation: 本发明涉及包含一种或多种与特异于细胞表面标志物的抗体结合的CD1d复合物的化合物。 CD1d复合物包含CD1d，β2-微球蛋白分子，并且还可以包含与CD1d结合槽结合的抗原。 本发明进一步涉及用CD1d抗体化合物抑制或刺激免疫应答的方法，特别是抗肿瘤和自身免疫应答。
-
公开(公告)号：US09809654B2
公开(公告)日：2017-11-07
申请号：US10529221
申请日：2003-09-26
Applicant: Bruno Robert , Alena Donda , Valerie Cesson , Jean-Pierre Mach , Maurice Zauderer
Inventor： Bruno Robert , Alena Donda , Valerie Cesson , Jean-Pierre Mach , Maurice Zauderer
CPC classification number: C07K16/30 , C07K14/70539 , C07K2317/54 , C07K2317/55 , C07K2319/00
Abstract: The invention is directed to a compound comprising one or more CD1d complexes in association with an antibody specific for a cell surface marker. The CD1d complexes comprise a CD1d, a β2-microglobulin molecule, and may further comprise an antigen bound to the CD1d binding groove. The invention is further directed to methods of inhibiting or stimulating an immune response with the CD1d-antibody compounds, in particular anti-tumor and autoimmunity responses.
-
公开(公告)号：US09603922B2
公开(公告)日：2017-03-28
申请号：US12034737
申请日：2008-02-21
Applicant: Alena Donda , Jean-Pierre Mach , Kathrin Stirnemann
Inventor： Alena Donda , Jean-Pierre Mach , Kathrin Stirnemann
IPC: A61K39/385 , A61K39/39 , A61K39/00 , C07K16/32
CPC classification number: A61K39/385 , A61K39/39 , A61K2039/55516 , A61K2039/55561 , A61K2039/55572 , A61K2039/55594 , A61K2039/6018 , C07K16/32 , C07K2319/00
Abstract: The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CD1d complexes, in particular non-specific soluble CD1d complexes. Soluble CD1d complexes comprise a soluble CD1d polypeptide, a β2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the CD1d antigen binding groove, and in certain embodiments, an immunogen. The administration of compositions of the present invention affects the activity of CD1d-restricted NKT cells, and in particular, allows for multiple administrations without causing CD1d-restricted NKT cell anergy.
-
公开(公告)号：US20140242076A1
公开(公告)日：2014-08-28
申请号：US14130773
申请日：2012-07-06
Applicant: Jean Kadouche , Jean-Pierre Mach , Olivier Michielin , Vincent Zoete , Justyna Iwaszkiewicz , Martine Cerutti , Sylvie Choblet , Josee Golay
Inventor： Jean Kadouche , Jean-Pierre Mach , Olivier Michielin , Vincent Zoete , Justyna Iwaszkiewicz , Martine Cerutti , Sylvie Choblet , Josee Golay
IPC: C07K16/46
CPC classification number: C07K16/468 , C07K16/2833 , C07K16/2896 , C07K2317/31 , C07K2317/522 , C07K2317/55 , C07K2317/732
Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy/light chain mispairing.
Abstract translation: 本发明涉及包含在CH1和CL结构域的界面处具有突变的Fab片段的多特异性抗体构建体，所述突变防止重/轻链失配。
-
5.发明申请Compositions Comprising Fetal Hemoglobin and Bacterial Endotoxin and Optionally Additional Fetal Liver Components 有权组成包括胎儿血红蛋白和细菌内毒素和任选额外的胎肝组成公开(公告)号：US20080075742A1
公开(公告)日：2008-03-27
申请号：US10545500
申请日：2004-02-18
Applicant: Otto Westphal , Josette Mottier Westphal , Alexander Westphal , Thierry Walli , Reginald Gorczynski , Silke Muller , Jean-Pierre Mach , Alfred Hartman , Wolfgang Bessler , Petra Hofmann , Ulrich Zahringer , Christian Alexander , Ulrich vor dem Esche , Artur J. Ulmer , Antonio Verdini
Inventor： Otto Westphal , Josette Mottier Westphal , Alexander Westphal , Thierry Walli , Reginald Gorczynski , Silke Muller , Jean-Pierre Mach , Alfred Hartman , Wolfgang Bessler , Petra Hofmann , Ulrich Zahringer , Christian Alexander , Ulrich vor dem Esche , Artur J. Ulmer , Antonio Verdini
CPC classification number: A61K35/407 , A23L33/10 , A61K35/74 , A61K38/42 , A61K2300/00
Abstract: The present invention relates to a pharmaceutical composition representing a novel immunomodulating principle comprising bacterial endotoxin, fetal hemoglobin or more particularly a heme-free derivative or the γ-chain thereof, and optionally, components which are present in the fetal liver in addition to HbF. The composition is delivered to humans in a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention it was surprisingly found that endotoxin and fetal hemoglobin partial structures display a pronounced synergistic biomedical activity. The biomedical effect of fetal hemoglobin and its partial structures is surprisingly not based on a classical hemoglobin function as an oxygen transporter but related to a modulation of endotoxin-mediated bioactivity. This biomedical activity is surprisingly also observed after oral application of the composition. The composition of the invention finds a variety of applications which have in common the stimulation of the immune system and the reversion in polarization of cytokines and chemokines from a Th2-directed response to a Th1-type response. The proposed applications would therefore include the treatment of allergic conditions, malignancies, chronic infections, autoimmune phenomena and age-related imbalances.
Abstract translation: 本发明涉及代表包含细菌内毒素，胎儿血红蛋白或更特别是不含血红素的衍生物或其γ链，以及任选地除了HbF之外存在于胎肝中的成分的新型免疫调节原理的药物组合物。 组合物以药学上可接受的载体和/或稀释剂递送给人。 根据本发明，惊奇地发现内毒素和胎儿血红蛋白部分结构显示出显着的协同生物医学活性。 胎儿血红蛋白及其部分结构的生物医学效应令人惊奇地不是基于作为氧转运蛋白的经典血红蛋白功能，而是与内毒素介导的生物活性的调节有关。 在口服施用组合物后，也观察到该生物医学活性。 本发明的组合物发现了各种各样的应用，其具有共同的刺激免疫系统的作用，并且从对Th1型反应的Th2导向反应的细胞因子和趋化因子的极化反转。 因此，提出的申请将包括治疗过敏性疾病，恶性肿瘤，慢性感染，自身免疫现象和年龄相关的不平衡。
-
Patent Agency Ranking
公开(公告)号：US09631031B2
公开(公告)日：2017-04-25
申请号：US14130773
申请日：2012-07-06
Applicant: Jean Kadouche , Jean-Pierre Mach , Olivier Michielin , Vincent Zoete , Justyna Iwaszkiewicz , Martine Cerutti , Sylvie Choblet , Josee Golay
Inventor： Jean Kadouche , Jean-Pierre Mach , Olivier Michielin , Vincent Zoete , Justyna Iwaszkiewicz , Martine Cerutti , Sylvie Choblet , Josee Golay
CPC classification number: C07K16/468 , C07K16/2833 , C07K16/2896 , C07K2317/31 , C07K2317/522 , C07K2317/55 , C07K2317/732
Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy/light chain mispairing.
-
7.发明授权Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components 有权包含胎儿血红蛋白和细菌内毒素以及任选的额外的胎儿肝组分的组合物公开(公告)号：US07968103B2
公开(公告)日：2011-06-28
申请号：US10545500
申请日：2004-02-18
Applicant: Otto Westphal , Josette Westphal, legal representative , Alexander Westphal, legal representative , Thierry Walli , Reginald Gorczynski , Silke Muller , Jean-Pierre Mach , Alfred Hartman , Wolfgang Bessler , Petra Hofmann , Ulrich Zahringer , Christian Alexander , Ulrich vor dem Esche , Artur J. Ulmer , Antonio Verdini
Inventor： Otto Westphal , Thierry Walli , Reginald Gorczynski , Silke Muller , Jean-Pierre Mach , Alfred Hartman , Wolfgang Bessler , Petra Hofmann , Ulrich Zahringer , Christian Alexander , Ulrich vor dem Esche , Artur J. Ulmer , Antonio Verdini
CPC classification number: A61K35/407 , A23L33/10 , A61K35/74 , A61K38/42 , A61K2300/00
Abstract: The present invention relates to a pharmaceutical composition representing a novel immunomodulating principle comprising bacterial endotoxin, fetal hemoglobin or more particularly a heme-free derivative or the γ-chain thereof, and optionally, components which are present in the fetal liver in addition to HbF. The composition is delivered to humans in a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention it was surprisingly found that endotoxin and fetal hemoglobin partial structures display a pronounced synergistic biomedical activity. The biomedical effect of fetal hemoglobin and its partial structures is surprisingly not based on a classical hemoglobin function as an oxygen transporter but related to a modulation of endotoxin-mediated bioactivity. This biomedical activity is surprisingly also observed after oral application of the composition. The composition of the invention finds a variety of applications which have in common the stimulation of the immune system and the reversion in polarization of cytokines and chemokines from a Th2-directed response to a Th1-type response. The proposed applications would therefore include the treatment of allergic conditions, malignancies, chronic infections, autoimmune phenomena and age-related imbalances.
Abstract translation: 本发明涉及代表包含细菌内毒素，胎儿血红蛋白或更特别是不含血红素的衍生物或其γ-链以及除HbF之外存在于胎肝中的成分的新型免疫调节原理的药物组合物。 组合物以药学上可接受的载体和/或稀释剂递送给人。 根据本发明，惊奇地发现内毒素和胎儿血红蛋白部分结构显示出显着的协同生物医学活性。 胎儿血红蛋白及其部分结构的生物医学效应令人惊奇地不是基于作为氧转运蛋白的经典血红蛋白功能，而是与内毒素介导的生物活性的调节有关。 在口服施用组合物后，也观察到该生物医学活性。 本发明的组合物发现了各种各样的应用，其具有共同的刺激免疫系统的作用，并且从对Th1型反应的Th2导向反应的细胞因子和趋化因子的极化反转。 因此，提出的申请将包括治疗过敏性疾病，恶性肿瘤，慢性感染，自身免疫现象和年龄相关的不平衡。
-
公开(公告)号：US20080254045A1
公开(公告)日：2008-10-16
申请号：US12034737
申请日：2008-02-21
Applicant: Alena DONDA , Jean-Pierre MACH , Kathrin STIRNEMANN , Maurice ZAUDERER
Inventor： Alena DONDA , Jean-Pierre MACH , Kathrin STIRNEMANN , Maurice ZAUDERER
IPC: A61K39/395 , A61K39/00 , A61K38/00 , A61P37/00 , C12N5/06
CPC classification number: A61K39/385 , A61K39/39 , A61K2039/55516 , A61K2039/55561 , A61K2039/55572 , A61K2039/55594 , A61K2039/6018 , C07K16/32 , C07K2319/00
Abstract: The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CD1d complexes, in particular non-specific soluble CD1d complexes. Soluble CD1d complexes comprise a soluble CD1d polypeptide, a β2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the CD1d antigen binding groove, and in certain embodiments, an immunogen. The administration of compositions of the present invention affects the activity of CD1d-restricted NKT cells, and in particular, allows for multiple administrations without causing CD1d-restricted NKT cell anergy.
Abstract translation: 本发明涉及调节动物免疫应答的方法，包括施用包含一种或多种可溶性CD1d复合物，特别是非特异性可溶性CD1d复合物的组合物。 可溶性CD1d复合物包含与CD1d抗原结合槽结合的可溶性CD1d多肽，β2-微球蛋白多肽和神经酰胺样糖脂抗原，并且在某些实施方案中，是免疫原。 本发明组合物的施用影响CD1d限制性NKT细胞的活性，特别是允许多次施用而不引起CD1d限制的NKT细胞无反应性。
-
9.发明授权Monoclonal antibodies with specificity affinity for human carcinoembryonic antigen 失效对人癌胚抗原具有特异性亲和力的单克隆抗体
公开(公告)号：US5047507A
公开(公告)日：1991-09-10
申请号：US293467
申请日：1989-01-04
Applicant: Franz Buchegger , Jean-Pierre Mach
Inventor： Franz Buchegger , Jean-Pierre Mach
IPC: G01N33/574 , A61K38/00 , A61K39/395 , A61P35/00 , C07K16/30 , C12N5/10 , C12N5/20 , C12N15/02 , C12P21/08 , C12R1/91 , G01N33/577
CPC classification number: C07K16/3007 , A61K38/00
Abstract: The invention concerns novel monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the preparation of these antibodies and their derivatives, hybridoma cell lines secreting the antibodies, and processes for the preparation of said cell lines. The monoclonal antibodies of the invention and their derivatives are useful in the diagnosis and therapy of cancer and serial monitoring of cancer patients for recurrent disease or response to therapy. Test kits and pharmaceutical compositions containing said monoclonal anti-CEA antibodies are also subject of the invention.
-
公开(公告)号：US20100105876A1
公开(公告)日：2010-04-29
申请号：US10132533
申请日：2002-04-25
Applicant: Alexey Terskikh , Reto Crameri , Jean-Pierre Mach , Jean-Marc Le Doussal , Andrey Kajava
Inventor： Alexey Terskikh , Reto Crameri , Jean-Pierre Mach , Jean-Marc Le Doussal , Andrey Kajava
CPC classification number: C07K14/78 , C07K19/00 , C07K2319/00 , C07K2319/21 , C07K2319/73 , C12N15/62
Abstract: The present invention concerns an oligomer comprising more than 2 units, wherein each unit comprises a peptidic domain capable of oligomerizing and a domain capable of binding to an acceptor (ligand), wherein the oligomerizing domain is not an antibody or a functional antibody fragment from the constant region. Also described is the use and synthesis of this oligomer.
Abstract translation: 本发明涉及包含多于2个单元的寡聚体，其中每个单元包括能够低聚的肽结构域和能够结合受体（配体）的结构域，其中所述寡聚结构域不是抗体或功能性抗体片段 恒定区。 还描述了该低聚物的用途和合成。
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.059 seconds)
